219 related articles for article (PubMed ID: 38630132)
21. Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special considerations.
Swan D; Rocci A; Bradbury C; Thachil J
Br J Haematol; 2018 Nov; 183(4):538-556. PubMed ID: 30450656
[TBL] [Abstract][Full Text] [Related]
22. A retrospective cohort study of venous thromboembolism(VTE) in 1035 Japanese myeloma patients treated with thalidomide; lower incidence without statistically significant association between specific risk factors and development of VTE and effects of thromboprophylaxis with aspirin and warfarin.
Kato A; Takano H; Ichikawa A; Koshino M; Igarashi A; Hattori K; Nagata K
Thromb Res; 2013 Feb; 131(2):140-4. PubMed ID: 23232090
[TBL] [Abstract][Full Text] [Related]
23. Interventions for implementation of thromboprophylaxis in hospitalized medical and surgical patients at risk for venous thromboembolism.
Kahn SR; Morrison DR; Cohen JM; Emed J; Tagalakis V; Roussin A; Geerts W
Cochrane Database Syst Rev; 2013 Jul; (7):CD008201. PubMed ID: 23861035
[TBL] [Abstract][Full Text] [Related]
24. Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.
Mahan CE; Burnett AE; Fletcher ML; Spyropoulos AC
Hosp Pract (1995); 2018 Feb; 46(1):5-15. PubMed ID: 29171776
[TBL] [Abstract][Full Text] [Related]
25. Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study.
Covut F; Ahmed R; Chawla S; Ricaurte F; Samaras CJ; Anwer F; Garcia AVM; Angelini DE; Mazzoni S; Faiman B; Valent J; Khouri J
Br J Haematol; 2021 Jun; 193(6):1213-1219. PubMed ID: 33997961
[TBL] [Abstract][Full Text] [Related]
26. Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials.
Thaler J; Ay C; Pabinger I
Thromb Haemost; 2012 Dec; 108(6):1042-8. PubMed ID: 22836491
[TBL] [Abstract][Full Text] [Related]
27. Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis.
Anaissie EJ; Coleman EA; Goodwin JA; Kennedy RL; Lockhart KD; Stewart CB; Coon SK; Bailey C; Barlogie B
Cancer; 2012 Jan; 118(2):549-57. PubMed ID: 21720994
[TBL] [Abstract][Full Text] [Related]
28. Formal and informal venous thromboembolism risk assessment and impact on prescribing of thromboprophylaxis: a retrospective cohort study.
Kemp M; Chan AHY; Harrison J; Rogers H; Zhao A; Kaur H; Tang G; Yang E; Beyene K
Int J Clin Pharm; 2023 Aug; 45(4):864-874. PubMed ID: 37074512
[TBL] [Abstract][Full Text] [Related]
29. Risk factors for inpatient venous thromboembolism despite thromboprophylaxis.
Wang TF; Wong CA; Milligan PE; Thoelke MS; Woeltje KF; Gage BF
Thromb Res; 2014 Jan; 133(1):25-9. PubMed ID: 24300584
[TBL] [Abstract][Full Text] [Related]
30. Incorrect use of thromboprophylaxis for venous thromboembolism in medical and surgical patients: results of a multicentric, observational and cross-sectional study in Brazil.
Deheinzelin D; Braga AL; Martins LC; Martins MA; Hernandez A; Yoshida WB; Maffei F; Monachini M; Calderaro D; Campos W; Sguizzatto GT; Caramelli B;
J Thromb Haemost; 2006 Jun; 4(6):1266-70. PubMed ID: 16706970
[TBL] [Abstract][Full Text] [Related]
31. Venous thromboembolism in cancer patients.
Deng A; Galanis T; Graham MG
Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
[TBL] [Abstract][Full Text] [Related]
32. Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma.
Baljevic M; Sborov DW; Lim MY; Hillengass J; Martin T; Castillo JJ; Streiff MB; Kumar SK; Callander NS
J Natl Compr Canc Netw; 2022 Jan; 20(1):91-95. PubMed ID: 34991076
[TBL] [Abstract][Full Text] [Related]
33. Direct oral anticoagulants versus aspirin for primary thromboprophylaxis in patients with multiple myeloma undergoing outpatient therapy: A systematic review and updated meta-analysis.
Costa TA; Felix N; Costa BA; Godoi A; Nogueira A; Rossi A
Br J Haematol; 2023 Nov; 203(3):395-403. PubMed ID: 37533165
[TBL] [Abstract][Full Text] [Related]
34. Different strategies for pharmacological thromboprophylaxis for lower-limb immobilisation after injury: systematic review and economic evaluation.
Pandor A; Horner D; Davis S; Goodacre S; Stevens JW; Clowes M; Hunt BJ; Nokes T; Keenan J; de Wit K
Health Technol Assess; 2019 Dec; 23(63):1-190. PubMed ID: 31851608
[TBL] [Abstract][Full Text] [Related]
35. The use of direct oral anticoagulants for thromboprophylaxis or treatment of cancer-associated venous thromboembolism: a meta-analysis and review of the guidelines.
Alsubaie NS; Al Rammah SM; Alshouimi RA; Alzahrani MY; Al Yami MS; Almutairi AR; Alfayez OM; Korayem GB; Almohammed OA
Thromb J; 2021 Oct; 19(1):76. PubMed ID: 34717653
[TBL] [Abstract][Full Text] [Related]
36. Death Associated with Inadequate Reassessment of Venous Thromboembolism Prophylaxis at and after Hospital Discharge.
Alta RN; 2015; 71(3):26-8. PubMed ID: 26638268
[TBL] [Abstract][Full Text] [Related]
37. Risk assessment and primary prevention of VTE in patients with cancer: Advances, challenges, and evidence gaps.
Steiner D; Ay C
Best Pract Res Clin Haematol; 2022 Mar; 35(1):101347. PubMed ID: 36030066
[TBL] [Abstract][Full Text] [Related]
38. Venous thromboembolism and risk stratification in hematological malignancies.
Sanfilippo KM
Thromb Res; 2022 May; 213 Suppl 1():S16-S21. PubMed ID: 36210555
[TBL] [Abstract][Full Text] [Related]
39. Venous and Arterial Thromboembolism in Patients With Cancer:
Gervaso L; Dave H; Khorana AA
JACC CardioOncol; 2021 Jun; 3(2):173-190. PubMed ID: 34396323
[TBL] [Abstract][Full Text] [Related]
40. D-dimer predicts venous thromboembolism in multiple myeloma: a nested case-control study.
Sanfilippo KM; Fiala MA; Feinberg D; Tathireddy H; Girard T; Vij R; Di Paola J; Gage BF
Res Pract Thromb Haemost; 2023 Nov; 7(8):102235. PubMed ID: 38193055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
